Kornimate/medical-research-clean huggingface dataset:
impact of an intervention of screening, treatment initiation and referral to promote smoking cessation in emergency department patients

Conditions: Tobacco Cessation

Summary: smoking cessation assistance is one of the major issues in prevention policies because the prevalence of smoking remains high in france. with its numerous consultations, an emergency service seems to be an interesting place for setting up and helping with weaning, despite specific working conditions. the study, which is a pilot, is interested in the feasibility and efficacy of the implementation of a stir (screening, treatment intervention and referral) protocol, which screening, brief intervention, nicotine replacement therapy and referral to a specialist in order to help the patients in smoking cessation.

individual randomization as soon as the patient gives his consent and meets the inclusion - non-inclusion criteria. control group: delivery of the "tobacco-info-service" brochure titled "why quit smoking? ", then phone call at 7 days and a month to collect tobacco consumption. visit for 3 month. intervention group: stir protocol (screening, brief intervention, incentive to download the tobacco info service application, delivery of the "tobacco-info-service" brochure, initiation of a nicotine replacement therapy with nicotine patches made by a trained emergency nurse or doctor, then three consultations face-to-face or remotely with a member of the team addictionology at 7 days, 1 and 3 months. in both groups: collection of the primary endpoint during the m3 visit. for patients who did not come (regardless of the group): call for collection of the main judgment criterion carers will be included and will sign a consent form once the eligibility criteria have been checked and consent has been signed. they will be asked to complete an adherence questionnaire (likert scale) regarding smoking prevention in emergency departments before the start of the study and after the last patient follow-up has taken place.

Eligibility criteria:
inclusion criteria: * age \>= to 18 years old * active smoker defined by having smoked at least 100 cigarettes in total in his life, associated with daily consumption or weekly * free and informed consent signed by the patient * patient with an understanding of the french language to participate in the intervention if necessary * patient affiliated to a social security regimen care giver inclusion criteria: * age ≥ 18 years * caregiver working in one of the 3 departments participating in the study * signature of free and informed consent exclusion criteria: * absolute vital emergency * pregnant or breastfeeding women * contraindication to taking nicotine * taking nicotine by patch or gum or e-cigarette * patient under ame (national medical insurance) * patients under guardianship

Keywords: emergency medicine public health addictionology smoking cessation tobacco dependence treatment
improving cerebral blood flow and cognitive function in patients with asymptomatic intracranial / carotid stenosis with nattokinase (icc-pacs)

Conditions: Cerebral Blood Flow; Cognitive Function

Summary: a randomized controlled trial will be conducted. patients with asymptomatic intracranial / carotid stenosis will be randomized into two arms (1:1): an intervention arm and a control arm. patients in the intervention arm will be treated with standard medical treatment combined with natto products v, whereas patient in the control arm will be treated with only standard medical treatment . and the impact of natto products v on improving cerebral blood flow and cognitive function in patients with asymptomatic intracranial / carotid stenosis will be assessed by neuropsychological scale and multimode magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: * patients aged ≥ 40 years * ≥ 50% stenosis in unilateral intracranial / carotid artery * written informed consent available exclusion criteria: * previous history of major head trauma and any intracranial surgery * intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions * extrapyramidal symptoms or mental illness which may affect neuropsychological measurement * severe loss of vision, hearing, or communicative ability * plan to be treated with surgery

Keywords: intracranial / carotid stenosis cerebral blood flow cognitive function
intervention to facilitate mmt/hiv service decentralization in vietnam

Conditions: Opioid-use Disorder

Summary: vietnam is currently decentralizing its methadone maintenance therapy (mmt) dispensing network to its local commune health centers (chc), which provides a window of opportunity to study decentralization of harm reduction and hiv-related healthcare services into community-based healthcare settings. commune health workers (chw) in vietnam have widespread misconceptions about harm reduction and perceived significant challenges associated with treating people who use drugs. intervention effort is needed to address these issues to ensure a smooth implementation of the decentralized service model. this study is to pilot testing an intervention with a primary focus on process optimization in six chc-based mmt distribution sites with 30 chw and 90 mmt patients. the six chc in thai nguyen province of vietnam will be randomized to either an intervention condition or a control condition. the intervention will be executed through a combination of in-person training and mobile phone application utilization. the intervention outcomes on chw and mmt clients will be evaluated at baseline, 3-, and 6-months.

the intervention pilot will be conducted in six commune health center (chc)-based methadone maintenance therapy (mmt) distribution sites in thai nguyen province of vietnam. five commune health workers (chw) and 15 mmt clients will be recruited from each of the chc (total n = 30 chw and 90 mmt clients). the six chc will be matched into pairs based on the current number of chw and mmt patient load; and within each pair, the two chc will be randomized into either a control condition or an intervention condition. the intervention contents will include the promotion of streamlined procedure, skill training, problem solving, knowledge acquisition, networking and support, and information sharing. the intervention will be delivered through a combination of service provider in-person training and mobile phone application utilization. provider-level outcomes (e.g., chw's mmt/hiv service provision) and client-level outcomes (e.g., treatment progress) will be measured at baseline, 3-, and 6-month follow-ups.

Eligibility criteria:
mmt patients (n=90): inclusion criteria: * age 18 or over * currently seeking mmt services in one of the participating commune health centers * voluntary informed consent exclusion criteria: * having psychosis or neurological damage, or cannot understand the study purposes as judged by the recruiter in consultation with a clinic supervisor. * inability to give informed consent chw (n=30): inclusion criteria: * age 18 or over * currently working in one of the participating commune health centers and have direct contact with mmt clients * providing informed consent exclusion criteria: • inability to provide informed consent

Keywords: vietnam service decentralization methadone maintenance therapy hiv community health setting
steady state kinetics of l-methamphetamine and validation of sensitivity of dose estimation

Conditions: Nasal Congestion

Summary: the intent of this study is to see if the rate that the body breaks down l-methamphetamine (l-ma) could be used as an accurate estimate for the rate that the body breaks down d-methamphetamine (d-ma). l-ma is sold over the counter as a nasal decongestant where as d-ma is the commonly abused form of methamphetamine.

subjects will screen at st. luke's hospital in san francisco to determine their eligibility. once enrolled the study will take two weeks. during the first week subjects attend daily, hour-long outpatient visits at san francisco general hospital. at these visits subjects will receive an oral dose of l-methamphetamine, have their vitals read, answer questionnaires and receive a blood draw. during the second week of the study subjects are admitted to san francisco general hospital for a week long inpatient stay. during this stay the subject continues to receive l-methamphetamine but also receives three doses of d-methamphetamine on three separate days. in addition the subject receives blood draws, has their urine collected, and answers questionnaires.

Eligibility criteria:
inclusion criteria: * healthy males and females between the ages of 18 and 50 * must have some experience with methamphetamine

Keywords: methamphetamine inpatient d-ma l-ma aprl san francisco metabolism metabolism of methamphetamine
the q-reduce study

Conditions: THA; Dislocation, Hip; PROM

Summary: the purpose of this study is to design a fast-track pathway for patients referred to the university hospital of southern denmark, esbjerg, with high probability of having a dislocated hip prosthesis with the primary aim to reduce the time from arrival to reduction and the total hospitalization time. secondary aims are to * investigate whether quicker prosthesis reduction influences on hip function and quality of life afterwards * reduce the pain experience immediately and in the long term * increase patient satisfaction without changing the overall complication rate and readmission/mortality


Eligibility criteria:
inclusion criteria: * a history of either a tha or a ha in combination with at least one of the following terms * having sustained a sudden, incorrect movement or twist in the hip joint in either a bending, sitting or supine position leading to inability to stand or walk * misalignment of the concerned lower extremity (typically shortened, with inward/outward rotation) exclusion criteria: * recurrent dislocations during the same hospital admission (already "in the house") * anticipated difficult airway by the attending anesthesiologist * anticipated need for extended respiratory or hemodynamic monitoring by the attending anesthesiologist * american society of anesthesiologists (asa) score \> 3 * body mass index (bmi) \> 40 * active drug abuse * contraindication for propofol or esketamine
inclusive invasive physiological assessment in angina syndromes registry

Conditions: Coronary Artery Disease; Microvascular Coronary Artery Disease

Summary: this study evaluates the prognostic value and potential therapeutic impact of combined pressure and flow measurements in the evaluation of epicardial coronary stenosis and microvascular function.

ilias registry is a global effort to gather lesion-level data on the diagnostic and prognostic value of combined coronary pressure and flow measurements in clinical practice. data is gathered from 7 nations (the netherlands, korea, japan, spain, italy, denmark, usa), using either coronary doppler velocity measurements or coronary thermodilution measurements to obtain invasive coronary flow assessment. patient treatment was governed by the local clinical practice guidelines at the time of the invasive procedure, but was at the operator's discretion. a standardized data collection sheet was used and all study adopted standardized definition of patient's baseline characteristics, clinical outcomes, and physiologic data. in case of acute coronary syndrome (unstable angina, non-st-segment elevation myocardial infarction, and st-segment elevation myocardial infarction), only non-culprit vessel evaluation was used.

Eligibility criteria:
inclusion criteria: * underwent combined measurements of coronary pressure and flow for at least 1native coronary artery exclusion criteria: * hemodynamic instability * culprit vessel of acute coronary syndrome

Keywords: coronary flow reserve fractional flow reserve microvascular resistance thermodilution doppler flow velocity
evaluation of usability and safety of the system atalante in patients with high paraplegia and tetraplegia

Conditions: Spinal Cord Injury; Tetraplegia/Tetraparesis; Paraplegia, Complete; Paraplegia, Incomplete; Guillain Barré Syndrome

Summary: the objective of this clinical trial is to determine whether the atalante x exoskeleton can be safely utilized by patients with tetraplegia and high paraplegia (at or above t4).


Eligibility criteria:
inclusion criteria: * ≥18 years old, * tetraplegia or high paraplegia (at or above t4) regardless of the cause, * non-opposition to the participation to the study, * having undergone a minimum of 1 session with the atalante device from february 2019, to now. exclusion criteria: * neurological level of injury below t4 as determined by the international standards for neurological classification of sci

Keywords: hands-free exoskeleton atalante x atalante rehabilitation safety
a study of intravenous tamiflu (oseltamivir) in children with influenza

Conditions: Influenza

Summary: this open-label study will assess the pharmacokinetics/pharmacodynamics and safety of intravenous (iv) tamiflu (oseltamivir) in 3 cohorts of children, aged 6-12, 3-5 and 1-2 years, with influenza infection. patients will receive iv tamiflu therapy for 5 days (10 doses). for patients whose conditions no longer merit continued iv dosing, therapy may be switched to oral tamiflu to complete their prescribed course of treatment. if medically necessary, iv or oral therapy with tamiflu may be continued for up to 5 additional days. anticipated time on study treatment is 5 to 10 days.


Eligibility criteria:
inclusion criteria: * children, 1-12 years of age * diagnosis of influenza * duration of influenza symptoms \</=96 hours prior to first dose of study drug exclusion criteria: * evidence of severe hepatic decompensation * patients taking probenecid within 1 week prior to first dose of study drug
mtg201 plus nivolumab in patients with relapsed pleural mesothelioma

Conditions: Malignant Pleural Mesothelioma

Summary: twelve patients with relapsed malignant pleural mesothelioma will be treated with intratumoral injections of mtg201, a replication incompetent adenovirus, modified by the insertion of the reduced expression in immortalized cells (reic)/dikkopf (dkk)-3 gene, on days 1, 8, 22, and 50. patients will also receive every 4 weekly intravenous infusions of nivolumab, 480 mg, starting on day 2. safety and anti-tumor activity will be monitored at regular intervals throughout the study.

this is a study of the efficacy and safety of mtg201 given by intratumoral injection to patients with malignant pleural mesothelioma who have failed front line chemotherapy. patients will also receive iv infusions of nivolumab every 4 weeks. mtg201 is a replication incompetent adenovirus into which the gene for reic/dkk-3 has been inserted. the insertion of this gene has been shown to endow the adenovirus with anti-tumor activity and to result in enhanced anti-tumor immunity. mtg201, 3 x 10e12 vp, will be given by intratumoral injection on days 1, 8, 22 and 50. nivolumab, 480 mg, will be given by iv infusion every 4 weeks until progression. efficacy will be assessed by ct scans at 4 and 12 weeks, then every 3 months. safety will be assessed by reported adverse events, periodic laboratory assessments, physical exams, vital signs. the pharmacokinetics and pharmacodynamics of mtg201 will be assessed periodically. tumor biopsy will be obtained on days 1, 8 and 50 prior to mtg201 administration.

Eligibility criteria:
inclusion criteria: * histologically confirmed locally advanced or metastatic pleural mesothelioma * failed one prior treatment regimen including cisplatin-based chemotherapy * eastern cooperative oncology group (ecog) performance status; 0,1 * adequate organ function * measurable disease per recist exclusion criteria: * candidate for surgical resection * has active autoimmune disease, primary or acquired immunodeficiency * significant cardiovascular disease * has active interstitial lung disease * has active infection or hiv, hepatitis b or c * previous anti-pd-1, pd-l1 or ctla-4 inhibitor immunotherapy * other clinical significant disorder that could affect conduct of study
effects of probiotics (p. pentosaceus, l. lactis or l. helveticus) in nash

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: a study for evaluating the improvement effect of non-alcoholic steatohepatitis (nash) of probiotics

non-alcoholic fatty liver disease progresses to fatty liver, hepatitis, cirrhosis, and liver cancer, resulting in a high mortality rate. the prevalence of non-alcoholic fatty liver disease at home and abroad is a major social and economic burden. however, there is no cure for non-alcoholic fatty liver disease. recently, intestinal axis theory related to the development of chronic liver disease and microbial community has emerged. intake of probiotics is known to play a role in regulating gut microflora. improvement of non-alcoholic fatty liver disease can be expected through administration of probiotics.

Eligibility criteria:
inclusion criteria: 1. those who agreed to participate in this study and signed a written consent 2. adult men and women over 20 3. patients diagnosed with non-alcoholic fatty liver ※ exclusion criteria for alcoholic liver disease * those who have an alcoholic drinking ability of at least 60g per day for at least one year before visiting (30g for women) * 1 bottle of shochu 360 ml \* 20% = 72 g, 1 bottle of beer 500 ml (330 ml for commercial use) \* 5% = 25 (16.5 g) 4. patients with higher liver numbers than normal ※ adult normal liver level range by enzyme * ast, alt: 40 or less * alp: 20-130 * got: 0-30, gpt: 0-38 * ggt: 10-62 (male), 7-35 (female) exclusion criteria: 1. those who have consumed probiotics (lactic acid bacteria, etc.), prebiotics (dietary fiber, fructooligosaccharide, etc.), new biotics, fermented milk, etc. within the past month. 2. those who have continuously taken antibiotics within the last 2 months or who are likely to take them during the study period 3. those who have continuously consumed medicines or health functional foods that affect liver function within the past month. 4. those who have participated in other clinical trials within the past 1 month (but not applicable to medical device clinical trials) 5. if you have any of the following * alcoholic liver disease, hereditary metabolic disease, autoimmune hepatitis * systemic inflammatory disease or immune disease * hepatocellular carcinoma * uncontrolled cardiopulmonary disease * other serious systemic disorders in the heart, lungs, blood, and endocrine system 6. a person with a history of malignancy diagnosis within the last 5 years 7. pregnant or lactating women 8. persons who have hypersensitivity to the test drug / placebo or components contained in the test drug / placebo or have severe allergic reactions 9. those who are not suitable for the clinical trial because the investigator judges

Keywords: probiotics liver disease gut microbiota
effect of transcutaneous auricular vagal nerve stimulation on functional dyspepsia

Conditions: Functional Dyspepsia

Summary: patients with dyspeptic symptoms vary from 10% to 20% globally. up to 70% of patients with dyspepsia who undergo endoscopy have unremarkable examination and are diagnosed with functional dyspepsia (fd). given the lack of information related to its pathophysiology, the treatment is largely empirical and of limited efficacy. previous small study showed therapeutic potential of transcutaneous auricular vagal nerve stimulation (tavns) for fd. this study aims to investigate whether tavns can improve the dyspeptic symptoms of patients with fd.


Eligibility criteria:
inclusion criteria: 1. 18-65 years old 2. patients who met the rome iv diagnostic criteria of fd 3. moderate to severe fd (functional dyspepsia symptom diary ≥10) 4. normal upper endoscopy and abdominal ultrasonography within one year. exclusion criteria: 1. injury or inflammation on the ear 2. asthma or copd not under control 3. history of cardiac pacemaker planting or other medical digital devices 4. history of vns treatment 5. patients with local or systemic diseases which may cause dyspeptic symptoms: known active peptic ulcer, cholecystitis, gallstone, gastrointestinal obstruction, gastroparesis, and etc.; known acute or chronic injury of liver or kidney; obvious hematological abnormality, or endocrine and metabolic diseases; known malignancy; obvious cardiovascular or cerebrovascular diseases (such as coronary heart disease, arrhythmia, cerebral infarction and etc.; other conditions which may be associated with dyspeptic symptoms (such as nsaids associated dyspepsia) 6. patients with serious mental disorders or tendency to suicide 7. pregnancy or lactic women 8. inability to give informed consent

Keywords: functional dyspepsia
screening of the frailty degree in the emergency department short stay unit

Conditions: Frail Elderly Syndrome

Summary: screen all those\> 65 years of age admitted to the short stay unit for frailty, and detect those who are potentially fragile.

demographic change has led to a change in the profile and age of hospitalized patients, an increase in age and in patients with multiple chronic diseases and more complex health needs is observed. frailty is known to impact patient health outcomes with medical and surgical procedures. thus, frailty is correlated with a greater presence of delirium, longer stays, a greater requirement for complementary examinations, a greater presence of mortality and other post-surgical complications, more dependence, more risks derived from hospitalization, and a greater need for convalescence after discharge.

Eligibility criteria:
inclusion criteria: * patients over 65 years of age admitted to the short stay unit exclusion criteria: * patients under 65 years of age admitted to the short stay unit

Keywords: elderly frailty short stay unit
investigation of the relationship between imagery ability, balance and functionality after stroke

Conditions: Stroke; Motor İmagery Ability; Mental Chronometry; Balance; Functionality

Summary: it was aimed to determine the relationship between post-stroke imagination ability, balance, and functionality, and to compare the motor imagery skills of those who had stroke with compatible healthy individuals.

i̇n the study, 20 individuals with hemiplegic or chronic hemiparesis who agreed to participate by signing the voluntary consent form, who meet the inclusion criteria, and 20 healthy individuals who are similar in terms of age, gender and education level will be included. the individuals included in the study will be divided into two groups: group 1: stroke patients group 2: control group

Eligibility criteria:
inclusion criteria: * post-stroke hemiplegia or chronic hemiparesis * not having any neurological disorder other than stroke * not having vision problems that will affect the materials to be used during the treatment. * to be able to communicate enough to understand the orders given * standardized mini mental test (smmt) score of 24 and above * not having seen a visualization application before inclusion criteria for healthy participants: * being between the ages of 40-80 * to be similar in terms of age, gender, education level of individuals with stroke exclusion criteria: * having an advanced degree of aphasia * unilateral neglect * standardized mini mental test (smmt) score below 24 points * multiple stroke history * having pain and limitation of joint motion that will interfere with functional activity * walking restriction * serious communication or understanding problems * presence of serious cardiovascular, respiratory, metabolic or orthopedic problems * presence of a secondary neurological disease

Keywords: stroke motor imagery mental chronometry balance functionality